119 related articles for article (PubMed ID: 12113049)
1. Troxacitabine-based therapy of refractory leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):261-6. PubMed ID: 12113049
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
[TBL] [Abstract][Full Text] [Related]
3. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
4. [Troxacitabine].
Gourdeau H; Jolivet J
Bull Cancer; 2004 Mar; 91(3):213-8. PubMed ID: 15171046
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
7. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Giles FJ; Kantarjian HM; Cortes JE; Garcia-Manero G; Verstovsek S; Faderl S; Thomas DA; Ferrajoli A; O'Brien S; Wathen JK; Xiao LC; Berry DA; Estey EH
J Clin Oncol; 2003 May; 21(9):1722-7. PubMed ID: 12721247
[TBL] [Abstract][Full Text] [Related]
8. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
[TBL] [Abstract][Full Text] [Related]
9. Troxacitabine in leukemia.
Swords R; Apostolidou E; Giles F
Hematology; 2006 Oct; 11(5):321-9. PubMed ID: 17607581
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
[TBL] [Abstract][Full Text] [Related]
11. Troxacitabine in acute leukemia.
Swords R; Giles F
Hematology; 2007 Jun; 12(3):219-27. PubMed ID: 17558697
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
13. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
14. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM; Estey E; Beran M
Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
[TBL] [Abstract][Full Text] [Related]
15. Troxacitabine (Shire Pharmaceuticals).
Ecker G
Curr Opin Investig Drugs; 2002 Oct; 3(10):1533-8. PubMed ID: 12431032
[TBL] [Abstract][Full Text] [Related]
16. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E
Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Investig Drugs; 2007 Apr; 16(4):547-57. PubMed ID: 17371201
[TBL] [Abstract][Full Text] [Related]
19. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
20. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
